Supplementary Figure S3. Treatment with KIN-3248 is well-tolerated when administered orally at doses up to 15 mg/kg daily. Data are from the CCLP-1 model engineered with the FGFR2-PHGDH fusion (n=8 mice/group) and are presented as mean ± SEM.
No takes yet. Share an insight, caveat, or question.
Balasooriya et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: